Bhatt Padmanabh P. 4

What Happened

• Bhatt Padmanabh P., Senior Vice President of IP and Chief Science Officer at Supernus Pharmaceuticals (SUPN), received derivative awards on February 18, 2026 totaling 16,500 units: 13,500 and 3,000 shares reported at $0.00 (no cash paid at grant). These are award/grant (code A) entries on a Form 4 filed Feb 20, 2026. Because these are awards (not open-market purchases or sales), they represent compensation/long-term incentives rather than an immediate market trade.

Key Details

• Transaction date: February 18, 2026; Form 4 filed: February 20, 2026 (filed within the SEC’s 2-business-day window).
• Reported items: 13,500 and 3,000 derivative units granted, price reported $0.00; total immediate cash outlay reported $0.
• Vesting/settlement: Footnotes indicate restricted stock units (RSUs) are settled in common stock upon vesting and vest in four equal annual installments beginning February 18, 2027 (footnotes F3 and F4). A separate award/option also vests in four equal annual installments beginning February 18, 2027 (footnote F2).
• Holdings note: Footnote F1 states the reporting person’s holdings include 392 shares acquired through the company’s Employee Stock Purchase Plan (ESPP).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Filing timeliness: Appears timely (Feb 20 filing for Feb 18 transaction).

Context

• These are grant/award (derivative) transactions — common executive compensation that vests over time. They do not represent an immediate buy or sale of publicly traded shares; value will be realized only if and when awards vest and are settled (at which point market value will determine worth). For retail investors, awards signal management compensation structure but are less informative about near-term insider sentiment than open-market purchases or sales.